Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

#8482;; the timing of the announcement of clinical results and potential regulatory filings by Baxter Healthcare for BAX 855; the timing of availability of topline overall survival data for the NKTR-102 BEACON study; and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and app
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... presenting at the Morgan Stanley Global Healthcare Conference on ... Nevro management is scheduled to present at ... a live audio webcast, accessible in the "Investors" section ...
(Date:9/3/2015)... -- WellCare Health Plans, Inc. (NYSE: WCG ) today ... and chief financial officer, is scheduled to present at ... September 9, 2015, at 9:25 a.m. Eastern time. ... a replay of the webcast will be available following ... broadcast and the replay will be available on the ...
(Date:9/3/2015)... Denmark , Sept. 3, 2015 /PRNewswire/ ... a clinical stage biotechnology company that applies ... unmet medical needs, today announced plans to ... 2015 Wells Fargo Healthcare Conference in BostonDate: ... EDTEvent: , Bank of America Merrill Lynch ...
Breaking Medicine Technology:Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... of evaluable heavily-pretreated patients in the high dose ... tolerated overall.DALLAS, March 5 ACCESS PHARMACEUTICALS, ... safety and efficacy results from its Phase 2 ... heavily pretreated ovarian cancer patients. In this monotherapy ...
... March 4 A new study by researchers at ... essential B vitamins, including B6, B12, and folic acid, ... of the leading causes of vision loss among older ... key omega-3 fatty acids and phytosterols, are also contained ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2
(Date:9/3/2015)... VA (PRWEB) , ... September 03, 2015 , ... ... the Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two ... members. Hope For The Warriors® is a national nonprofit dedicated to restoring a ...
(Date:9/3/2015)... ... September 03, 2015 , ... For many patients with lymphedema, ... compression garments are an effective solution for reducing the medical costs associated with ... sponsored by SIGVARIS for a unique opportunity to meet with Jim ...
(Date:9/3/2015)... ... 03, 2015 , ... RealtyShares , the online marketplace ... investors to real estate investment opportunities nationwide, today announced that it is introducing ... and sponsoring real estate companies. , These products typically involve investors ...
(Date:9/3/2015)... ... , ... The first part of a two-part investigative news segment aired last ... filed against Bard.** These lawsuits, filed by persons and the family members of ... have recently been consolidated for pretrial proceedings as multidistrict litigation, MDL 2641 Bard IVC ...
(Date:9/3/2015)... MO (PRWEB) , ... September 03, 2015 , ... The ... NASA’s mission control, the surface of a comet, the IceCube observatory at the South ... the way. , The Fall Lecture Series for the world's foremost independently funded ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5
... Altered Security Settings Leaving Them Open to Significant Risk , ... ... systems isn,t getting any easier, according to the results of the ... The recent study details how users often dismiss internal security ...
... in southeastern Turkey have discovered an Iron Age chiseled ... the region that people believed the soul was separate ... describe the discovery, a testimony created by an Iron ... man, on Nov. 22-23 at conferences of biblical and ...
... a leader in enabling the development of DNA ... its partner, Tripep AB, reported positive additional interim ... of its therapeutic DNA vaccine against hepatitis C ... Inovio’s electroporation-based DNA delivery system. In the third ...
... network and healthcare information resource, today released the ... between increasing healthcare costs and more infrequent doctor ... (54 percent) indicated they are going to the ... rising healthcare costs. In an additional question of ...
... facility is extending lives and saving the health-care system ... In analyzing the cost-effectiveness of Vancouver-based Insite, a safe ... injection drug users live, researchers found $14 million in ... years. , Published in the November 18 edition of ...
... women to have reconstruction after mastectomy , , MONDAY, Nov. ... are more likely to have immediate breast reconstruction than ... This is also true for more educated women and ... women and those who live in predominantly black neighborhoods ...
Cached Medicine News:Health News:Lumension Uncovers Results of Security Data Protection Survey 2Health News:Lumension Uncovers Results of Security Data Protection Survey 3Health News:Funerary monument reveals Iron Age belief that the soul lived in the stone 2Health News:Funerary monument reveals Iron Age belief that the soul lived in the stone 3Health News:Funerary monument reveals Iron Age belief that the soul lived in the stone 4Health News: Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 2Health News: Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 3Health News: Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% : Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases 4Health News: More Than Half of Consumers Going to Doctors Less Due to Rising Healthcare Costs, According to checkMD Survey : 38 Percent Lack Adequate Employer Healthcare Coverage 2Health News: More Than Half of Consumers Going to Doctors Less Due to Rising Healthcare Costs, According to checkMD Survey : 38 Percent Lack Adequate Employer Healthcare Coverage 3Health News:Study finds Canada's supervised injection facility cost-effective 2Health News:Wealthy More Likely to Have Breast Reconstruction 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: